Levetiracetam-induced pediatric toxic epidermal necrolysis successfully treated with etanercept

Pediatr Dermatol. 2020 Jul;37(4):701-705. doi: 10.1111/pde.14179. Epub 2020 Apr 22.

Abstract

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

Keywords: anti-tumor necrosis factor (TNF); etanercept; levetiracetam; toxic epidermal necrolysis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Child
  • Etanercept / adverse effects
  • Humans
  • Immunoglobulins, Intravenous
  • Infliximab
  • Levetiracetam
  • Male
  • Stevens-Johnson Syndrome* / diagnosis
  • Stevens-Johnson Syndrome* / drug therapy
  • Stevens-Johnson Syndrome* / etiology
  • Tumor Necrosis Factor-alpha

Substances

  • Immunoglobulins, Intravenous
  • Tumor Necrosis Factor-alpha
  • Levetiracetam
  • Infliximab
  • Etanercept